FDA Orange Book
Is there a generic for Locametz?
Locametz contains gallium ga-68 gozetotide. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
No. The Orange Book lists no active FDA-approved generic (ANDA) for Locametz (gallium ga-68 gozetotide). The Orange Book shows its last listed patent expires March 9, 2036.
Run it in Rivvi
Map Locametz and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Locametz products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| powder, intravenous | N/A | Marketed (Rx) | None | 0 | None |
NDA 215841, held by NOVARTIS PHARMACEUTICALS CORP. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Locametz patents
| Patent | Expires | Covers | Use code | NDA |
|---|---|---|---|---|
| 11369590 | August 15, 2028 | Drug substance, Drug product | U-3400 | 215841 |
| 12109277 | March 9, 2036 | Method of use | U-4002 | 215841 |
Locametz NDC codes
Questions
Is there a generic for Locametz?
No. The Orange Book lists no active FDA-approved generic (ANDA) for Locametz (gallium ga-68 gozetotide). The Orange Book shows its last listed patent expires March 9, 2036.
What is the generic name for Locametz?
The active ingredient in Locametz is gallium ga-68 gozetotide, per the FDA Orange Book.
When does the Locametz patent expire?
The last patent listed for Locametz in the Orange Book expires March 9, 2036. A listed patent expiry date is not a generic launch date.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.